PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12415476

Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit.

A P Johnson·L Tysall·M V Stockdale·N Woodford·M E Kaufmann·M Warner·D M Livermore·F Asboth·F J Allerberger
View original source ↗Export metadata ↓

Abstract

Of two patients in the same intensive care unit who were treated with linezolid, one yielded linezolid-resistant Enterococcus faecalis, whereas the other yielded linezolid-resistant Enterococcus faecium. In each case, molecular typing indicated that the resistant isolates were related to linezolid-susceptible isolates from the same patient, but differed from them by the same G2576U ribosomal RNA mutation. This is the first clinical case report of emerging resistance to linezolid among Enterococcus faecalis and also the first report of resistance involving vancomycin-susceptible rather than vancomycin-resistant enterococci. The linezolid-resistant isolates showed cross-resistance to the experimental oxazolidinone AZD2563, suggesting that oxazolidinone resistance might be a class effect.

Explore related subjects

AcetamidesAgedAnti-Bacterial AgentsAustriaBase SequenceCross InfectionDNA, BacterialDrug Resistance, MicrobialEnterococcus faecalisEnterococcus faeciumGram-Positive Bacterial InfectionsHumansIntensive Care UnitsLinezolidMaleMicrobial Sensitivity TestsMiddle AgedMolecular Sequence DataOxazolidinonesPolymerase Chain ReactionSensitivity and SpecificityCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A P Johnson, L Tysall, M V Stockdale, N Woodford, M E Kaufmann, M Warner, D M Livermore, F Asboth, F J Allerberger. 2002-09-13. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit.. https://doi.org/10.1007/s10096-002-0807-0

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists.

A series of biphenylaminocyclopropane carboxamide based bradykinin B1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant. Discovery that the replacement of the trifluoropropionamide in the lead structure with polyhaloacetamides, particularly a trifluoroacetamide, significantly reduced P-glycoprotein mediated efflux for the series proved essential. One of these novel bradykinin B1 antagonists (13b) also exhibited suitable pharmacokinetic properties and efficient ex vivo receptor occupancy for further development as a novel approach for the treatment of pain and inflammation.

Acetamides↗
PubMed2007

Spontaneous enzymatically mediated dynamic kinetic resolution of 8-amino-5,6,7,8-tetrahydroquinoline.

A spontaneous dynamic kinetic resolution of 8-amino-5,6,7,8-tetrahydroquinoline 1 was observed in the presence of Candida antarctica Lipase B, in which a >60% yield of (R)-acetamide [(R)-2] was isolated from the racemic amine. The spontaneous formation of ketone 3, followed by a condensation/hydrolysis sequence with the remaining (S)-amine 1, via enamine 4, provides the necessary racemization pathway.

Acetamides↗
PubMed2007

Total synthesis of bistramide A.

An asymmetric synthesis of the marine metabolite bistramide A is reported. The synthesis relies on the utility of three different organosilane reagents to construct all principle fragments and 8 of the 11 stereogenic centers of the natural product. [structure: see text].

Acetamides↗